<?xml version='1.0' encoding='utf-8'?>
<document id="20814789"><sentence text="The small-molecule tyrosine kinase inhibitor nilotinib is a potent noncompetitive inhibitor of the SN-38 glucuronidation by human UGT1A1."><entity charOffset="19-27" id="DDI-PubMed.20814789.s1.e0" text="tyrosine" /><entity charOffset="45-54" id="DDI-PubMed.20814789.s1.e1" text="nilotinib" /><pair ddi="false" e1="DDI-PubMed.20814789.s1.e0" e2="DDI-PubMed.20814789.s1.e0" /><pair ddi="false" e1="DDI-PubMed.20814789.s1.e0" e2="DDI-PubMed.20814789.s1.e1" /></sentence><sentence text="Inhibition of the UDP-glucuronosyltransferase (UGT) 1A1 by nilotinib was examined in vitro with SN-38 as a substrate, to estimate the possibility of drug-drug interaction of nilotinib with other medicines predominantly detoxified by UGT1A1"><entity charOffset="59-68" id="DDI-PubMed.20814789.s2.e0" text="nilotinib" /><entity charOffset="174-183" id="DDI-PubMed.20814789.s2.e1" text="nilotinib" /><pair ddi="false" e1="DDI-PubMed.20814789.s2.e0" e2="DDI-PubMed.20814789.s2.e0" /><pair ddi="false" e1="DDI-PubMed.20814789.s2.e0" e2="DDI-PubMed.20814789.s2.e1" /></sentence><sentence text="" /><sentence text="Inhibition of UGT1A1-catalyzed SN-38 glucuronidation by nilotinib was examined with human liver microsomes (HLM) and recombinant human UGT1A1 as enzyme sources"><entity charOffset="56-65" id="DDI-PubMed.20814789.s4.e0" text="nilotinib" /></sentence><sentence text=" Inhibition constants (K(i)) were estimated with kinetic analysis" /><sentence text="" /><sentence text="Nilotinib potently inhibited the SN-38 glucuronidation by human liver microsomal UGT1A1 and recombinant UGT1A1 in a noncompetitive manner, with K(i) values of 0"><entity charOffset="0-9" id="DDI-PubMed.20814789.s7.e0" text="Nilotinib" /></sentence><sentence text="286 ± 0" /><sentence text="0094 and 0" /><sentence text="079 ± 0" /><sentence text="0029 μM, respectively" /><sentence text=" If a drug that serves as a substrate of UGT1A1 is administered with nilotinib, the area under the plasma concentration-time curve of a drug estimated by using these K(i) values would be two times or higher than that without nilotinib, suggesting drug-drug interactions involving UGT1A1"><entity charOffset="69-78" id="DDI-PubMed.20814789.s12.e0" text="nilotinib" /><entity charOffset="225-234" id="DDI-PubMed.20814789.s12.e1" text="nilotinib" /><pair ddi="false" e1="DDI-PubMed.20814789.s12.e0" e2="DDI-PubMed.20814789.s12.e0" /><pair ddi="false" e1="DDI-PubMed.20814789.s12.e0" e2="DDI-PubMed.20814789.s12.e1" /></sentence><sentence text=" These in vitro data and the prediction of drug-drug interaction are helpful for the clinical management of the nilotinib use"><entity charOffset="112-121" id="DDI-PubMed.20814789.s13.e0" text="nilotinib" /></sentence><sentence text="" /><sentence text="We found that nilotinib is a potent noncompetitive inhibitor of human UGT1A1 activity"><entity charOffset="14-23" id="DDI-PubMed.20814789.s15.e0" text="nilotinib" /></sentence><sentence text="" /></document>